tbuckley/cabot-search huggingface dataset:
In-hospital mortality in acute promyelocytic leukemia patients: A study of national inpatient sample.
Authors: Dipesh Uprety, Yazhini Vallatharasu, Amir Bista, Mamatha Gaddam, Andrew J Borgert, Lori J. Rosenstein
Journal: Journal of Clinical Oncology (2019)

e18521 Background: Acute Promyelocytic Leukemia (APL), a subtype of acute myeloid leukemia, has excellent outcomes, but continues to show high rates of early mortality. An epidemiologic study utilizing SEER between 1992 &amp; 2007 showed an early death rate of 17.3%. There is limited data on the incidence of inpatient mortality in APL patients in the United States and the factors that contribute to early death. Methods: National Inpatient Sample was utilized to identify adult patients (≥18 years) diagnosed with APL using International Classification of Diseases, 10 th edition (ICD-10-CM) code C92.40. Since the United States transitioned from using ICD-9-CM to ICD-10-CM on October 2015, we included APL patients diagnosed between 2015 &amp; 2016. Clinical, sociodemographic and hospital characteristic data were examined; hospital volume was divided into quartiles. The association between overall inpatient survival &amp; receipt of chemotherapy was examined in a propensity score matched cohort of patients not discharged to another acute care facility. Statistical analyses were conducted utilizing SAS version 9.4. Results: In total, 433 APL patients were identified (median age 52 years, 52% males, 65% whites). The inpatient mortality rate was 9.93%. 59.5% (n = 258) of patients did not receive chemotherapy. On univariate-analysis, patients with younger age, black-race, transfer in from other hospital, elective admissions, private insurance, large bed size hospital &amp; large hospital volume were more likely to receive chemo. In the matched-cohort, receipt of chemo was associated with decreased mortality (Hazard Ratio 0.27, 95% CI: 0.12-0.60). We ran additional mortality analysis landmarked at 3 days and 7 days: 75% of chemo patients receiving treatment within 3 days had survival advantage with chemo (HR: 0.35 [0.15-0.82]). 90% of chemo patients receiving treatment within 7 days didn’t show any difference in survival (HR: 0.49 [0.18-1.32]) but the sample size was small. Conclusions: Our study showed an early survival benefit when patient with APL received chemotherapy within 3 days of admission. Early recognition &amp; prompt treatment initiation will help reduce the rate of early mortality in patients with APL.
Immediate and delayed coronary angiography did not differ for survival after OHCA without STEMI
Authors: Saraschandra Vallabhajosyula, Malcolm R. Bell
Journal: Annals of Internal Medicine (2019)

ACP Journal Club16 July 2019Immediate and delayed coronary angiography did not differ for survival after OHCA without STEMISaraschandra Vallabhajosyula, MD, Malcolm R. Bell, MDSaraschandra Vallabhajosyula, MDMayo Clinic, Rochester, Minnesota, USA (S.V., M.R.B.)Search for more papers by this author, Malcolm R. Bell, MDMayo Clinic, Rochester, Minnesota, USA (S.V., M.R.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ201907160-004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380:1397-1407. https://pubmed.ncbi.nlm.nih.gov/30883057Clinical Impact RatingsEmergency Med: Cardiology: References1 Callaway CW, Donnino MW, Fink EL, et al. Part 8: Post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S465-82. [PMID: 26472996] Google Scholar2 Jentzer JC, Herrmann J, Prasad A, Barsness GW, Bell MR. Utility and challenges of an early invasive strategy in patients resuscitated from out-of-hospital cardiac arrest. JACC Cardiovasc Interv. 2019;12:697-708. [PMID: 31000007] Google Scholar3 Sasson C, Rogers MA, Dahl J, Kellermann AL. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3:63-81. [PMID: 20123673] Google Scholar4 Bougouin W, Dumas F, Karam N, et al; Sudden Death Expertise Center. Should we perform an immediate coronary angiogram in all patients after cardiac arrest?: Insights from a large French registry. JACC Cardiovasc Interv. 2018;11:249-56. [PMID: 29413238] Google Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic, Rochester, Minnesota, USA (S.V., M.R.B.)This article was published at Annals.org on 2 July 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byWeekend Effect in the Management and Outcomes of Acute Myocardial Infarction in the United States, 2000-2016Reporting of sex as a variable in cardiovascular studies using cultured cells: A systematic reviewCardiac Arrest Definition Using Administrative Codes and Outcomes in Acute Myocardial Infarction 16 July 2019Volume 171, Issue 2Page: JC4KeywordsAngiographyHeartMortalityOdds ratioPatient advocacyPercutaneous coronary interventionResearch laboratoriesSafetyShockSt segment elevation myocardial infarction ePublished: 16 July 2019 Issue Published: 16 July 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Authors: Franck Morschhauser, Steven Le Gouill, Pierre Feugier, Sarah Bailly, Emmanuelle Nicolas-Virelizier, Fontanet Bijou, Gilles A Salles, Hervé Tilly, Christophe Fruchart, Koen Van Eygen, Sylvia Snauwaert, Christophe Bonnet, Corinne Haioun, Catherine Thieblemont, Reda Bouabdallah, Ka Lung Wu, Danielle Canioni, Véronique Meignin, Guillaume Cartron, Roch Houot
Journal: The Lancet Haematology (2019)
Interactions Between Influenza and Heart Failure Hospitalizations—Diagnostic and Pathogenetic Issues—Reply
Authors: Sonja Kytömaa, Sheila Hegde, Orly Vardeny
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Incidental Detection of Adrenal Pheochromocytoma on 99mTc-DTPA Renal Dynamic Scintigraphy
Authors: Yanxia Mi, Jianmin Huang, Yuan Ren, Peng Xie
Journal: Clinical Nuclear Medicine (2019)

Abstract A 53-year-old man with a history of primary hypertension for over 8 years underwent 99m Tc-DTPA renal dynamic scintigraphy to evaluate the renal function. The images revealed an unexpected focus of abnormally increased DTPA activity in the region superior to the upper pole of the right kidney. Subsequent MRIs confirmed an adrenal mass. The results of pathological examination and immunohistochemistry after the resection of the lesion were consistent with adrenal pheochromocytoma.
Scientific claims are constitutive of common sense about health
Authors: Nada Gligorov
Journal: Behavioral and Brain Sciences (2019)

Abstract Endorsing the view that commonsense conceptions are shaped by scientific claims provides an explanation for why microbiota-gut-brain (MGB) research might become incorporated into commonsense notions of health. But scientific claims also shape notions of personal identity, which accounts for why they can become entrenched in common sense even after they have been refuted by science.
Stromal integrin α11 regulates PDGFRβ signaling and promotes breast cancer progression
Authors: Irina Primac, Erik Maquoi, Silvia Blacher, Ritva Heljasvaara, Jan Van Deun, Hilde Y.H. Smeland, Annalisa Canale, Thomas Louis, Linda Stuhr, Nor Eddine Sounni, Didier Cataldo, Taina Pihlajaniemi, Christel Pequeux, Olivier De Wever, Donald Gullberg, Agnès Noel
Journal: Journal of Clinical Investigation (2019)

Cancer-associated fibroblasts (CAFs) are key actors in modulating the progression of many solid tumors such as breast cancer (BC). Herein, we identify an integrin α11/PDGFRβ+ CAF subset displaying tumor-promoting features in BC. In the preclinical MMTV-PyMT mouse model, integrin α11-deficiency led to a drastic reduction of tumor progression and metastasis. A clear association between integrin α11 and PDGFRβ was found at both transcriptional and histological levels in BC specimens. High stromal integrin α11/PDGFRβ expression was associated with high grades and poorer clinical outcome in human BC patients. Functional assays using five CAF subpopulations (one murine, four human) revealed that integrin α11 promotes CAF invasion and CAF-induced tumor cell invasion upon PDGF-BB stimulation. Mechanistically, integrin α11 pro-invasive activity relies on its ability to interact with PDGFRβ in a ligand-dependent manner and to promote its downstream JNK activation, leading to the production of tenascin C, a pro-invasive matricellular protein. Pharmacological inhibition of PDGFRβ and JNK impaired tumor cell invasion induced by integrin α11-positive CAFs. Collectively, our study uncovers an integrin α11-positive subset of pro-tumoral CAFs that exploits PDGFRβ/JNK signalling axis to promote tumor invasiveness in BC.
Maternal alloimmune IgG causes anti-glomerular basement membrane disease in perinatal transgenic mice that express human laminin α5
Authors: Dale R. Abrahamson, Brooke M. Steenhard, Larysa Stroganova, Adrian Zelenchuk, Patricia L. St. John, Margaret G. Petroff, Manuel Patarroyo, Dorin Bogdan Borza
Journal: Kidney International (2019)
Treatment to prevent exacerbations in bronchiectasis: macrolides as first line?
Authors: Irena F. Laska, James D. Chalmers
Journal: European Respiratory Journal (2019)

Bronchiectasis exacerbations are defined by an increase in daily respiratory symptoms such as cough, sputum production, malaise, fatigue and breathlessness [1–3]. Symptoms accumulate over several days and can take weeks to resolve, with many patients never fully returning to baseline after therapy [4]. Patients with frequent exacerbations experience poorer quality of life and a markedly increased mortality [5–7]. Patients tend to continue to have frequent exacerbations over time unless therapy is initiated to prevent them [5]. Bronchiectasis guidelines such as those recently issued from the European Respiratory Society (ERS) and British Thoracic Society therefore rightly prioritise exacerbation prevention as perhaps the key objective of therapy, alongside improvement of patients' symptoms and quality of life [8–10]. Macrolides appear to be superior to inhaled corticosteroids for exacerbation prevention in bronchiectasis patients <http://bit.ly/2Je3BY6>
The True Outcomes of Geriatric Trauma—If We Do Not Count Them, We Will Never Know
Authors: Vanessa P. Ho, Lisa Reider, Elliott R. Haut
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Outcomes of autologous blood collection prior to bone marrow harvest for matched unrelated donors.
Authors: Brian Hemendra Ramnaraign, Brittany Kayla Rogers, Susan P. McGorray, Michele Sugrue, Hemant S. Murthy, John W. Hiemenz, Jack W. Hsu, John R. Wingard, Nosha Farhadfar
Journal: Journal of Clinical Oncology (2019)

e18535 Background: Autologous (auto) blood collection prior to bone marrow (BM) harvest is a common procedure however there is little data to say whether this is beneficial. Methods: This is a retrospective study evaluating the efficacy of pre-op auto blood collection in healthy unrelated donors who underwent BM harvesting at our institution between 9/2009 and 8/2017. Unrelated donors aged 18 or older who underwent their first BM harvest were included. Comparisons were made using two sample t-tests. Results: Among the 73 BM donors, 54 (74%) underwent auto blood collection resulting in 78 units collected. The cohorts with and without auto blood collected were similar in age and gender (mean age 31.0 vs 30.2; female 59% vs 41%). Those with auto blood collected donated larger volumes of marrow (mean 1395 mL vs 799 mL, p = 0.0002). Baseline hemoglobin (Hb) was similar between the cohorts (mean 14.1 g/dL vs 14.0 g/dL, p = 0.87). However, those with auto blood collected had lower pre-harvest (mean 13.1 g/dL vs 13.8 g/dL, p = 0.0430) and post-harvest Hb (mean 10.0 g/dL vs 11.3 g/dL, p = 0.0120). Of the 78 auto blood units collected, 45 units (58%) were used with 92% of women and 56% of men receiving their auto blood post-op. 33 (42%) auto blood units were discarded. Donors who were given back their auto blood were more likely to be female and have lower pre- and post-harvest Hb. Reasons for auto blood transfusion were blood availability (31%), donor post-op symptoms (i.e. hypotension, dizziness, syncope, and bleeding; 23%), intra-operative transient hypotension (26%), post-op anemia (11%) and patient request (9%). None of the patients who were transfused auto blood, or donors without auto blood collection, required allogeneic blood. Conclusions: Based on our results, collection of auto blood prior to bone marrow harvest leads to lower pre-op Hb and increases the likelihood of post-op blood transfusion. In addition, availability of auto blood can lead to over transfusion which may be detrimental to donor health. Although there may be a subset of donors who might benefit, routine auto blood collection prior to bone marrow harvesting is unnecessary and can be potentially hazardous to donors.
Systolic Blood Pressure and Risk of Valvular Heart Disease
Authors: Milad Nazarzadeh, Ana-Catarina Pinho-Gomes, Karl Smith Byrne, Dexter Canoy, Francesca Raimondi, Jose Roberto Ayala Solares, Catherine M. Otto, Kazem Rahimi
Journal: JAMA Cardiology (2019)

<h3>Importance</h3> Modifiable risk factors for valvular heart disease remain largely unknown, which limits prevention and treatment. <h3>Objective</h3> To assess the association between systolic blood pressure (BP) and major valvular heart disease. <h3>Design, Setting, and Participants</h3> A UK Biobank population-based cohort of 502 602 men and women aged 40 to 96 years at baseline was evaluated through mendelian randomization using individual participant data. Inclusion criteria were valid genetic data and BP measurements. The participants were recruited between 2006 and 2010; data analysis was performed from June 2018 to January 2019. <h3>Exposures</h3> Systolic BP was measured during clinical assessment and instruments for the genetic effect of high BP were identified from variants that were independently (linkage disequilibrium threshold of<i>r</i><sup>2</sup>&lt;0.1) associated with systolic BP with minor allele frequency greater than 0.01. A total of 130 single-nucleotide polymorphisms that have been shown to be associated with systolic BP in a genome-wide association meta-analysis involving 1 million participants of European ancestry were selected. <h3>Main Outcomes and Measures</h3> Incident aortic stenosis, aortic regurgitation, and mitral regurgitation, individually and combined. Cases were largely based on hospital records linked to the UK Biobank with<i>International Classification of Diseases and Health Related Problems, Tenth Revision</i>codes. <h3>Results</h3> Of the 502 602 individuals screened, 329 237 participants (177 741 [53.99%] women; mean [SD] age, 56.93 [7.99] years) had valid genetic data and BP measurements; of this cohort, 3570 individuals (1.08%) had a diagnosis of valvular heart disease (aortic stenosis, 1491 [0.45%]; aortic regurgitation, 634 [0.19%]; and mitral regurgitation, 1736 [0.53%]). Each genetically associated 20–mm Hg increment in systolic BP was associated with an increased risk of aortic stenosis (odds ratio [OR], 3.26; 95% CI, 1.50-7.10), aortic regurgitation (OR, 2.59; 95% CI, 0.75-8.92), and mitral regurgitation (OR, 2.19; 95% CI, 1.07-4.47), with no evidence for heterogeneity by type of valvular heart disease (<i>P</i> = .90). Sensitivity analyses confirmed the robustness of the association. <h3>Conclusions and Relevance</h3> Lifetime exposure to elevated systolic BP appears to be associated with an increased risk of major valvular heart disease.
Proteinuria and Risk of Lower-Extremity Amputation in Patients With Peripheral Artery Disease
Authors: Jung-Im Shin, Morgan E. Grams, Josef Coresh, Alex R. Chang, Kunihiro Matsushita
Journal: Diabetes Care (2019)

Lower-extremity amputation (LEA) is a devastating complication of peripheral artery disease (PAD). Early identification of PAD patients at high risk of LEA is important to enable targeted monitoring and treatment strategies. Although chronic kidney disease is recognized as a high-risk condition for foot complications in diabetes, most previous studies focused on estimated glomerular filtration rate (eGFR). Proteinuria, a marker of kidney damage, has been less studied than eGFR in this context but is a promising predictor of LEA. A small cross-sectional study in the U.K. suggested that albuminuria was associated with foot ulceration in diabetes (1). A recent meta-analysis showed proteinuria as a strong independent predictor of incident PAD and LEA among those without PAD (2). However, whether proteinuria is associated with LEA among patients with diagnosed PAD is unknown. This is an important clinical question since most PAD patients have diabetes or hypertension, two major clinical conditions that merit proteinuria assessment according to clinical guidelines (3,4), and many of them should have data on proteinuria readily available.

Using data from the Geisinger Health System, a fully integrated rural health care system in Pennsylvania (1 March 1997–2 February 2017), we investigated the prospective association between dipstick proteinuria and risk …
Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis
Authors: Anna Maria van Eijk, Garazi Zulaika, Madeline Lenchner, Linda Mason, Muthusamy Sivakami, Elizabeth Nyothach, Holger Unger, Kayla Laserson, Penelope A Phillips-Howard
Journal: The Lancet Public Health (2019)

Girls and women need effective, safe, and affordable menstrual products. Single-use products are regularly selected by agencies for resource-poor settings; the menstrual cup is a less known alternative. We reviewed international studies on menstrual cup leakage, acceptability, and safety and explored menstrual cup availability to inform programmes.
A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.
Authors: Ciara Marie Kelly, Ping Chi, Mark Andrew Dickson, Mrinal M. Gounder, Mary Louise Keohan, Li-Xuan Qin, Travis Adamson, Mercedes M. Condy, Matthew Biniakewitz, Haley Phelan, Samuel Singer, Aimee Marie Crago, Sam S. Yoon, Charlotte Eielson Ariyan, Sinchun Hwang, Joseph Patrick Erinjeri, Cristina R. Antonescu, William D. Tap, Sandra P. D'Angelo
Journal: Journal of Clinical Oncology (2019)

11049 Background: Tumors express IDO1, an intracellular enzyme involved in the degradation of tryptophan to kynurenine, in order to evade immunosurveillance. Epacadostat inhibits IDO1 and shifts the tumor microenvironment from an immunosuppressive state to an immune-stimulated state. Pembrolizumab previously demonstrated activity in select sarcoma subtypes. We performed an open-label, single-center, phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Methods: Patients received the recommended phase II dose of oral epacadostat (100mg) twice per day and intravenous pembrolizumab (200mg/dose) every 3 weeks. The primary endpoint was best objective response rate (ORR) (complete response and partial response [PR]) at 24 weeks by RECIST 1.1. Secondary endpoints included adverse events (AEs), ORR by irRECIST, progression free survival (PFS) and overall survival (OS). Correlative studies performed on pre/on-treatment biopsy specimens included PD-L1, IDO1, and kynurenine expression and characterization of tumor infiltrating lymphocytes by IHC, whole exome and RNA sequencing. Results: Twenty-nine patients were enrolled [median age 53 years (range, 24-78), 57% male, ECOG PS 0 83%]. Histological subtypes included leiomyosarcoma (17%), UPS (17%), myxofibrosarcoma (7%), liposarcoma (10.5%), EHE (10.5%), angiosarcoma (3%), “other” sarcoma subtype (35%). Patients were refractory to 0 (21%), 1 (38%), 2 (24%) and ≥ 3 (17%) prior lines of therapy. The most common ( &gt; 20% of pts) grade (G)1 or 2 treatment related AEs (TRAEs) observed included fatigue (31%), rash (31%) and ALT elevation (24%). G3 TRAEs included AST elevation (10%), ALT elevation, anemia, hypophosphatemia and increased lipase each occurred in 3% of pts. Three patients discontinued therapy due to G3 immune mediated hepatitis. Among the 29 evaluable patients 1 (3%) confirmed PR (leiomyosarcoma), 13 stable diseases (45%) and 15 progressions (52%) were observed by RECIST 1.1. The median PFS was 8.0 weeks (two-sided 95% CI: 6.9 ~ 26.7) and the PFS rate at 24 weeks was 27.9% (two-sided 95% CI: 15.0% ~ 52.2%). The median OS was not estimable (two-sided 95% CI: 40.9 weeks ~ NE). The OS at 24 weeks was 85.2% (95% CI: 72.8%, 99.7%). Conclusions: Epacadostat in combination with pembrolizumab was generally well tolerated. Limited anti-tumor activity was observed among advanced sarcoma patients. Correlative analyses including determination of adequacy of IDO1 inhibition will be reported. Clinical trial information: NCT03414229.